Editas Medicine (EDIT) Shares Outstanding (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Shares Outstanding (Entity) of $97.9 million for Q4 2025, up 18.29% year-over-year from $82.7 million in Q4 2024, and up 4.93% quarter-over-quarter from $93.3 million in Q3 2025.
Editas Medicine (EDIT) Shares Outstanding (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Shares Outstanding (Entity) for 11 consecutive years, with $97.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) rose 18.29% year-over-year to $97.9 million; the TTM figure through Dec 2025 stood at $97.9 million (up 18.29% YoY), while the FY2025 annual figure was $97.9 million, up 18.29% from the prior year.
- Shares Outstanding (Entity) grew to $97.9 million in Q4 2025 per EDIT's latest filing, from $93.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $97.9 million in Q4 2025 and bottomed at $67.5 million in Q1 2021.
- Historically, Shares Outstanding (Entity) has averaged $77.7 million across 5 years, with a median of $81.6 million in 2023.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) gained 23.12% — and 2023, when it advanced 0.57%.
- Editas Medicine's Shares Outstanding (Entity) stood at $68.4 million in 2021, then advanced by 0.6% to $68.8 million in 2022, then increased by 18.77% to $81.8 million in 2023, then climbed by 1.18% to $82.7 million in 2024, then advanced by 18.29% to $97.9 million in 2025.
- Business Quant data shows EDIT's Shares Outstanding (Entity) at $97.9 million in Q4 2025, $93.3 million in Q3 2025, and $87.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 90.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 90.09 Mn |
| Sep 30, 2025 | 90.09 Mn |
| Jun 30, 2025 | 84.41 Mn |
| Mar 31, 2025 | 83.06 Mn |
| Dec 31, 2024 | 82.34 Mn |
| Sep 30, 2024 | 82.49 Mn |
| Jun 30, 2024 | 82.31 Mn |
| Mar 31, 2024 | 81.94 Mn |
| Dec 31, 2023 | 75.97 Mn |
| Sep 30, 2023 | 81.65 Mn |
| Jun 30, 2023 | 71.38 Mn |
| Mar 31, 2023 | 68.92 Mn |
| Dec 31, 2022 | 68.66 Mn |
| Sep 30, 2022 | 68.74 Mn |
| Jun 30, 2022 | 68.64 Mn |
| Mar 31, 2022 | 68.48 Mn |
| Dec 31, 2021 | 67.62 Mn |
| Sep 30, 2021 | 68.22 Mn |
| Jun 30, 2021 | 67.88 Mn |
| Mar 31, 2021 | 65.99 Mn |